24 A more recent double-blind, randomized, controlled trial that investigated the microvascular effects of linagliptin in nondiabetic patients with arterial hypertension resulted in a significant improvement in retinal capillary perfusion and retinal arterial blood flow
Report suspected adverse reactions via the MHRA Yellow Card scheme to support ongoing medication safety monitoring
More significant tissue healing and recovery benefits typically develop over 4 to 8 weeks of consistent use
Patient safety and product quality must remain the top priority, and FDA approval pathways play a critical role in ensuring clinical efficacy, proper dosing, and risk management
Lactic acidosis reports were markedly lower with combination therapy (567 vs 15,789), as were acute kidney injury (675 vs 7,694), diarrhoea (3,890 vs 6,922), and metabolic acidosis (203 vs 4,713), suggesting that the addition of GLP-1 RAs to metformin may mitigate serious adverse effects associated with metformin alone (Table 2)
ClinicalTrials.gov and the World Health Organization portal were also reviewed for ongoing or unpublished studies
